Alport syndrome and the polypharmacy problem in the practice of ENT specialists
R.N. MAMLEEV1, 2, A.V. SINCHUGOV2, R.M. ASADULLINA1
1Kazan State Medical University, Kazan
2Children’s Republican Clinical Hospital, Ministry of Health of Republic of Tatarstan, Kazan
Contact details:
Mamleev R.N. — PhD (medicine), Associate Professor of Department of Hospital Pediatrics
Address: 49 Butlerov St., Russian Federation, Kazan, 420012, tel.: +7-917-921-12-70, e-mail: r.mamleev@mail.ru
Genetically determined diseases, Alport syndrome in particular, are traditionally the object of polypharmacy. The addition of intercurrent infection aggravates this situation, since it requires comedication directed at the focus of infection. Multiple drug interactions, which lead to a weakening of the therapeutic effect of some drugs and increase the toxic potential of others, require attention from all participants of the therapeutic process.
Key words: Alport syndrome, acute otitis externa, polypharmacy.
REFERENCES
- Savige J., Ariani F., Mari F. et al. Expert consensus guidelines for the genetic diagnosis of Alport syndrome. PediatrNephrol, 2019, vol. 34 (7), pp. 1175–1189. DOI:10.1007/s00467-018-3985-4
- Wang F., Zhao D., Ding J., Li X. The First COL4A5 Exon 41A Glycine Substitution in a Family With Alport Syndrome. Front Pediatr, 2020, vol. 8, p. 153. Published 2020 Apr 9. DOI:10.3389/fped.2020.00153
- Alport A.C. Hereditary familial congenital haemorrhagic nephritis. Br. Med. J., 1927, vol. 1, pp. 504–506.
- Nagel M., Nagorka S., Gross O. Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome. Hum. Mutat., 20085, vol. 26, p. 60.
- Hertz J.M., Thomassen M., Storey H., Flinter F. Clinical utility gene card for: Alport syndrome. Eur J Hum Genet, 2012, vol. 20 (6). DOI:10.1038/ejhg.2011.237
- Gao E., Yang X., Si N., Liu K., Wang J.Q., Liu Z. A Novel COL4A5 Splicing Mutation Causes Skipping of Exon 14 in a Chinese Family with Alport Syndrome. Kidney Dis (Basel)., 2020, vol. 6 (1), pp. 43–49. DOI:10.1159/000502798
- Funk S.D., Bayer R.H., Miner J.H. Endothelial cell-specific collagen type IV-α3 expression does not rescue Alport syndrome in Col4a3-/- mice. Am J Physiol Renal Physiol., 2019, vol. 316 (5), pp. F830–F837. DOI:10.1152/ajprenal.00556.2018
- Shagam L.I., Shentseva D.V. Molecular genetic basis of the pathogenesis of Alport syndrome. Rossiyskiy vestnik perinatologii i pediatrii, 2013, no. 6, pp. 25–27.
- Rintelmann W. Auditory manifestations of Alport’s disease syndrome. Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol, 1976, vol. 82 (3 Pt 1), pp. 375–387.
- Gleeson M.J. Alport’s syndrome: audiological manifestations and implications. J Laryngol Otol, 1984, no. 98449, p. 465.
- Barilyak V.V., Mileshina N.A., Moskalets Yu.A., Generalova G.A., Markova M.V., Tsygankova E.R. Changes in auditory function in children with chronic kidney disease. Vestnik otorinolaringologii, 2018, vol. 83, no. 4, pp. 56–59 (in Russ.). DOI: org/10/17116/otorino201883456
- Weber P.C., Cunningham C.D. 3rd, Schulte B.A. Potassium recycling pathways in the human cochlea. Laryngoscope, 2001, vol. 111 (7), pp. 1156–1165. DOI: 10.1097/00005537-200107000-00006
- Harvey S.J., Mount R., Sado Y. et al. The inner ear of dogs with X-linked nephritis provides clues to the pathogenesis of hearing loss in X-linked Alport syndrome. Am J Pathol., 2001, vol. 159 (3), pp. 1097–1104. DOI: 10.1016/S0002-9440(10)61785-3
- Jais J.P., Knebelmann B., Giatras I. et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a «European Community Alport Syndrome Concerted Action» study. J Am Soc Nephrol, 2003, vol. 4 (10), pp. 2603–2610. DOI: 10.1097/01.asn.0000090034.71205.74
- Cadogan C., Ryan C., Gormley G., Passmore P., Francis J., Kerse N. et al. Dispensing appropriate polypharmacy to older people in primary care: a qualitative, theory-based study of community pharmacists’ perceptions and experiences. Int J Pharm Pract., 2015, vol. 23, p. 32. DOI: 10.1111/ijpp.12182
- Dlin V.V., Ignatov M.S., Kon’kova N.E. Clinical guidelines for the diagnosis and treatment of Alport syndrome in children. Nefrologiya, 2015, vol. 19, no. 3, pp. 86–89 (in Russ.). UDK: 616.61-053.32-056.7-07.08